RxDoctor Payments DataLook up a doctor →

Joshua Wilson, MD

Child & Adolescent Psychiatry · Saint Louis, MONPI 1609130061

Payments from drug & device makers

$203,774in general payments, 2019–2025

Across 1,375 payments — averaging $148.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$95K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$89K
  • AbbVie$4K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Johnson & Johnson$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • plus $12K from 32 others
$5,607in research payments, 2019–2025

Across 28 payments — averaging $200.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
  • Supernus Pharmaceuticals, Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka Pharmaceutical Development & Commercialization, Inc.5$94,913
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)138$88,916
AbbVie(2 entities)237$3,529
Otsuka America Pharmaceutical, Inc.128$1,817
Johnson & Johnson64$1,354
Supernus Pharmaceuticals, Inc.53$1,312
Axsome Therapeutics, Inc.67$1,307
Alkermes, Inc.69$1,146
Corium, LLC79$1,125
Teva Pharmaceuticals USA, Inc.38$1,050
Lundbeck LLC59$931
Vanda Pharmaceuticals Inc.63$883
Neurocrine Biosciences, Inc.46$848
Neos Therapeutics, LP66$777
Takeda Pharmaceuticals U.S.A., Inc.47$690
Tris Pharma Inc46$532
Ironshore Pharmaceuticals Inc.24$442
Rhodes Pharmaceuticals L.p.22$249
E.r. Squibb & Sons, L.L.C.19$245
Bausch Health US, LLC14$234
Noven Therapeutics, LLC19$227
Collegium Pharmaceutical, Inc.13$145
Almatica Pharma LLC7$137
Livanova USA, Inc.7$121
Sunovion Pharmaceuticals Inc.1$116
Vertical Pharmaceuticals, LLC8$109
Jazz Pharmaceuticals Inc.6$104
Merck5$92
Indivior Inc.4$67
Shire North American Group Inc4$66
Mayne Pharma Commercial LLC4$65
Adlon Therapeutics L.p.4$58
Eisai Inc.3$44
Genentech, Inc.1$40
Amgen2$34
TMS Neurohealth Centers Inc.1$21
Neuronetics, Inc.1$16
Aytu Biopharma, Inc.1$14

How this compares

$203,774 in reported general payments places this provider in the 95th percentile of 90 child & adolescent psychiatry providers in Missouri.

See all child & adolescent psychiatry providers in Missouri →

Medicare billing

Part B allowed, 2024
$51,001
Medicare patients
126
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other child & adolescent psychiatry in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →